Market closed
Entrada Therapeutics/$TRDA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Entrada Therapeutics
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Ticker
$TRDA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
168
Website
TRDA Metrics
BasicAdvanced
$661M
Market cap
12.03
P/E ratio
$1.55
EPS
-0.27
Beta
-
Dividend rate
Price and volume
Market cap
$661M
Beta
-0.27
52-week high
$18.17
52-week low
$10.75
Average daily volume
125K
Financial strength
Current ratio
6.591
Quick ratio
6.418
Long term debt to equity
12.682
Total debt to equity
14.514
Management effectiveness
Return on assets (TTM)
6.95%
Return on equity (TTM)
16.43%
Valuation
Price to earnings (TTM)
12.032
Price to revenue (TTM)
3.072
Price to book
1.56
Price to tangible book (TTM)
1.56
Price to free cash flow (TTM)
-37.859
Growth
Revenue change (TTM)
146.92%
Earnings per share change (TTM)
-331.32%
3-year earnings per share growth (CAGR)
-63.38%
What the Analysts think about TRDA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Entrada Therapeutics stock.
TRDA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TRDA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TRDA News
AllArticlesVideos
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
GlobeNewsWire·4 weeks ago
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
GlobeNewsWire·1 month ago
āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Entrada Therapeutics stock?
Entrada Therapeutics (TRDA) has a market cap of $661M as of November 08, 2024.
What is the P/E ratio for Entrada Therapeutics stock?
The price to earnings (P/E) ratio for Entrada Therapeutics (TRDA) stock is 12.03 as of November 08, 2024.
Does Entrada Therapeutics stock pay dividends?
No, Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Entrada Therapeutics dividend payment date?
Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Entrada Therapeutics?
Entrada Therapeutics (TRDA) has a beta rating of -0.27. This means that it has an inverse relation to market volatility.